首页 | 本学科首页   官方微博 | 高级检索  
     

Survivin致敏的树突状细胞疫苗激活抗白血病T细胞的实验研究
引用本文:张晓晖,夏凌辉,刘仲萍,魏文宁,胡豫,宋善俊. Survivin致敏的树突状细胞疫苗激活抗白血病T细胞的实验研究[J]. 中国实验血液学杂志, 2003, 11(1): 66-69
作者姓名:张晓晖  夏凌辉  刘仲萍  魏文宁  胡豫  宋善俊
作者单位:华中科技大学同济医学院附属协和医院血液科,武汉,430022
基金项目:山西省科技厅科研基金资助项目编号2 0 0 0 2 5 897
摘    要:
为研究survivin致敏树突状细胞(DC)疫苗对特异性T细胞的激活影响及对白血病细胞生长抑制作用,采用共聚焦显微镜及免疫沉淀-Western印迹等方法检测急性白血病细胞survivin表达;外周血单个核细胞体外培养,诱导DC细胞的形成;体外进行survivin抗原负载,制备survivin DC疫苗;survivin DC激发同基因型T细胞,用流式细胞术进一步分析T细胞表型;^3H-TdR法测定刺激指数(SI);并用^51Cr释放法测定特异性的抗白血病CTL细胞毒活性。结果表明,检测19例初治急性白血病患survivin的表达率为84.2%;其荧光分布均在细胞胞浆内;免疫沉淀-Western印迹进一步分析证实其survivin蛋白表达;外周血单个核细胞体外诱导形成的DC细胞具有典型的DC的形态学特征;survivinDC可显刺激T细胞的活化增殖;survivin激活的T细胞中,CD4^ TH比例显较DC组高,DC激发的T细胞则以表达CD8和CD56为主;同时survivinDC显抑制白血病细胞的生长。结论:急性白血病细胞表达survivin抗原,利用survivinDC疫苗可有效地抑制白血病细胞的生长,为DC治疗白血病开辟了一条新途径。

关 键 词:survivin 树突状细胞疫苗 抗白血病疫苗 急性白血病 T细胞
文章编号:1009-2137(2003)01-0066-04
修稿时间:2002-04-01

Experimental Study on Activating Antileukemic T Cells by Vaccination with Dendritic Cells Pulsed with Survivin
ZHANG Xiao Hui,XIA Ling Hui,LIU Zhong Ping,WEI Wen Ning,HU Yu,SONG Shan Jun. Experimental Study on Activating Antileukemic T Cells by Vaccination with Dendritic Cells Pulsed with Survivin[J]. Journal of experimental hematology, 2003, 11(1): 66-69
Authors:ZHANG Xiao Hui  XIA Ling Hui  LIU Zhong Ping  WEI Wen Ning  HU Yu  SONG Shan Jun
Affiliation:Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. zhangxh100@sina.com
Abstract:
The objective of this study is to investigate the effect of vaccination with dendritic cells pulsed with survivin antigen on activation of antileukemic T cells, and inhibiting proliferation of leukemic cells. The expression of survivin on acute leukemic cells were detected by cofocal microscopy and immunoprecipitation Western blot. DCs collected from peripheral blood mononuclear cells were pulsed with survivin purified proteins. Stimulation index (SI) and antileukemia CTL induction were analyzed with 3H TdR incorporation and 51 Cr releasing assay, respectively. The phenotype of T cells and DCs were identified by flow cytometry. By immunofluorescence of bone marrow and peripheral blood mononuclear cells, survivin expression was detected in 16 out of 19 AML cases (84.2%). The results showed that survivin fluorescence distribution was in cytoplasm. DCs from peripheral blood mononuclear cells were successfully induced, with typical DC morphologic characteristic. The vaccination with dendritic cells pulsed with survivin antigen dramatically stimulated the proliferation of T cells. The DCs loading survivin activated T cells with higher CD4 + T H ratio as compared with DCs group, T cells activated with DCs expressed CD8 and CD56. Survivin DCs significantly inhibited the growth of leukemic cells in vitro. In conclusion, survivin antigen expressed in the cytoplasm of leukemic cells, leukemic vaccination with DCs pulsed with survivin antigen in vitro inhibited the proliferation of leukemic cells, that may be a pathway for therapy of leukemia.
Keywords:survivin  DC vaccination  antileukemic vaccination  aute leukemia  T cell
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号